相关实验视频
Updated: Jun 22, 2026
10:28
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
Published on: June 26, 2020
9.6K
严重的肝脏相关的结果在患有型肝炎的患者:多民族多中心长期随访研究的结果
Arno Furquim d'Almeida1,2, Erwin Ho2, Liesbeth Govaerts2
1Viral Hepatitis Research Group, Laboratory of Experimental Medicine and Pediatrics, University of Antwerp, Antwerp, Belgium.
Journal of viral hepatitis
|January 23, 2025
概括
乙型肝炎病毒 (HBV) - 肝炎三角病毒 (HDV) 共感染是严重的. 高密度病毒RNA阳性和肝病标志物预测了共感染患者的严重结果,随着时间的推移影响了近四分之一.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 病毒学 病毒学
- 临床医学 临床医学
背景情况:
- 乙型肝炎病毒 (HBV) 与三角肝炎病毒 (HDV) 的联合感染是慢性病毒性肝炎的最严重形式.
- 在HBV-HDV共感染中影响疾病进展和严重程度的因素仍然不完全理解.
研究的目的:
- 确定HBV-HDV共感染患者严重肝脏相关结果的风险因素.
- 在长期同感染个体队列中描述疾病进展.
主要方法:
- 在一个多中心国家队列中,对162名HBV-HDV共感染患者的数据进行了回顾性分析.
- 纳入标准:HBsAg或HBVDNA阳性,抗HDV或HDVRNA阳性,并至少进行一次随访.
- 随访时间中位数为6.2年,数据收集于2001年至2023年之间.
主要成果:
- 44.7%的患者在基线时患有晚期肝纤维化.
- 在随访期间,24.7%的患者经历了至少一种严重的肝脏相关结果.
- 在基线,HDV RNA阳性与4.7倍更高的严重结局风险和更频繁的晚期纤维化有关.
结论:
- 几乎四分之一的HBV-HDV共感染患者出现严重的肝脏相关结果.
- 高密度病毒RNA阳性,基线晚期纤维化,INR,血小板计数和入院时的年龄是严重结果的独立预测因素.
- 了解这些预测因素可以帮助管理HBV-HDV共感染的严重肝病.
相关概念视频
01:26Diseases of the Liver and Gallbladder
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...